A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

Summary

This study is testing a lab-made antibody called ePGT121v1-LS that targets a specific part of HIV. Researchers will give it by vein (IV) and under the skin (SC), both on its own and together with two other antibodies, VRC07-523LS and PGDM1400LS, which target different parts of the virus. They will assess safety and side effects, determine the right dose, study how the body processes the drug (pharmacokinetics or PK), and measure how well it neutralizes HIV in the blood (serum neutralizing activity).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• HIV

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 55 years

Sex

All

Healthy volunteers

Accepted

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Last updated on ClinicalTrials.gov

September 1, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites